Metastasis Clinical Trials

25 recruiting

Metastasis Trials at a Glance

190 actively recruiting trials for metastasis are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Not Applicable with 54 trials, with the heaviest enrollment activity in Shanghai, Houston, and New York. Lead sponsors running metastasis studies include Guangzhou Medical University, Fudan University, and Sun Yat-sen University.

Browse metastasis trials by phase

Treatments under study

About Metastasis Clinical Trials

Looking for clinical trials for Metastasis? There are currently 25 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastasis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastasis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 190 trials

Recruiting
Not Applicable

Proton SBRT for Spinal Metastasis

Spinal Metastasis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins12 enrolled1 locationNCT06895564
Recruiting
Phase 3

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled317 locationsNCT07174336
Recruiting
Phase 1Phase 2

Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer

Leptomeningeal Metastasis From Lung Cancer
Henan Cancer Hospital14 enrolled1 locationNCT07559097
Recruiting
Not Applicable

Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA

Bladder CancerOligometastasisUrothelial Carcinoma (UC)
Istituto Clinico Humanitas44 enrolled1 locationNCT07413523
Recruiting
Phase 2

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Neoplasm MetastasisEndometrial NeoplasmsNeoplasm Recurrence, Local
Shandong Cancer Hospital and Institute30 enrolled1 locationNCT06532539
Recruiting
Not Applicable

Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

Leptomeningeal MetastasisLung Neoplasms, Non-Small Cell Lung Cancer
Second Affiliated Hospital of Nanchang University30 enrolled1 locationNCT07398599
Recruiting
Not Applicable

NK Cell Therapy for Malignant Solid Brain Tumors

Brain MetastasisGlioblastoma Multiforme (GBM)Glioblastoma (GBM)+2 more
Peking University Third Hospital27 enrolled4 locationsNCT07552233
Recruiting
Phase 1Phase 2

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

MetastasisCastration-Resistant Prostatic Cancer
Merck Sharp & Dohme LLC360 enrolled75 locationsNCT06863272
Recruiting
Phase 1Phase 2

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Metastatic Renal Cell CarcinomaCarcinoma, Renal CellAdvanced Renal Cell Carcinoma+8 more
Pfizer224 enrolled49 locationsNCT07227415
Recruiting
Phase 1

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
Eli Lilly and Company535 enrolled84 locationsNCT05614739
Recruiting
Phase 1

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Breast NeoplasmsColorectal NeoplasmsProstate Neoplasm+2 more
Eli Lilly and Company421 enrolled28 locationsNCT07114601
Recruiting
Phase 3

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,080 enrolled260 locationsNCT07213804
Recruiting
Phase 3

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled281 locationsNCT07218380
Recruiting
Phase 1

A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis

Spinal Metastasis
M.D. Anderson Cancer Center30 enrolled1 locationNCT06906900
Recruiting
Phase 2

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Stage IV Esophageal Cancer AJCC v7Stage IV Gastric Cancer AJCC v7Gastric Adenocarcinoma+2 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT03161522
Recruiting
Not Applicable

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

Liver CancerMelanomaMerkel Cell Carcinoma+9 more
Istituto Oncologico Veneto IRCCS24 enrolled1 locationNCT06753136
Recruiting
Phase 1Phase 2

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Breast CancerMetastasis
Icahn School of Medicine at Mount Sinai42 enrolled3 locationsNCT05095207
Recruiting
Phase 1Phase 2

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

MelanomaAdvanced Solid TumorMetastasis+5 more
7 Hills Pharma, LLC126 enrolled5 locationsNCT06362369
Recruiting

Effectiveness Of Radiofrequency Ablation And Stabilization In Metastatic Spine Lesions By Positron Emission Computed Tomography (PET-CT) Confirmation

Spine MetastasesRadiofrequency AblationBone Cancer Metastatic+1 more
National and Kapodistrian University of Athens16 enrolled1 locationNCT06716294
Recruiting
Not Applicable

Feasibility Study Incorporating Music Therapy to Optimise the Smoking Cessation Process Coordinated by a Tobacco Addiction Nurse in Smoking Patients Being Treated for Cancer

Cancer (With or Without Metastasis)
Institut du Cancer de Montpellier - Val d'Aurelle26 enrolled1 locationNCT07198971